QT interval prolongation related to psychoactive drug treatment: A comparison of monotherapy versus polytherapy

被引:82
|
作者
Sala M. [1 ]
Vicentini A. [2 ]
Brambilla P. [4 ]
Montomoli C. [3 ]
Jogia J.R.S. [6 ]
Caverzasi E. [1 ]
Bonzano A. [1 ]
Piccinelli M. [5 ]
Barale F. [1 ]
De Ferrari G. [2 ]
机构
[1] Department of Health Sciences, Section of Psychiatry, University of Pavia, Pavia
[2] Department of Cardiology, IRCCS Policlino S. Matteo, University of Pavia, Pavia
[3] Department of Health Sciences, University of Pavia, Pavia
[4] Department of Pathology and Experimental and Clinical Medicine, Section of Psychiatry, University of Udine, Udine
[5] Psychiatry Unit, Azienda Ospedaliera Universitaria Ospedale di Circolo, Fondazione Macchi di Varese, Varese
[6] Section of Neurobiology of Psychosis, Institute of Psychiatry, London
关键词
Antidepressant; Antipsychotic; Proarrhythmia; QTc interval;
D O I
10.1186/1744-859X-4-1
中图分类号
学科分类号
摘要
Background: Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias. Antipsychotic agents are often given in combination with other psychotropic drugs, such as antidepressants, that may also contribute to QT prolongation. This observational study compares the effects observed on QT interval between antipsychotic monotherapy and psychoactive polytherapy, which included an additional antidepressant or lithium treatment. Method: We examined two groups of hospitalized women with Schizophrenia, Bipolar Disorder and Schizoaffective Disorder in a naturalistic setting. Group 1 was composed of nineteen hospitalized women treated with antipsychotic monotherapy (either haloperidol, olanzapine, risperidone or clozapine) and Group 2 was composed of nineteen hospitalized women treated with an antipsychotic (either haloperidol, olanzapine, risperidone or quetiapine) with an additional antidepressant (citalopram, escitalopram, sertraline, paroxetine, fluvoxamine, mirtazapine, venlafaxine or clomipramine) or lithium. An Electrocardiogram (ECG) was carried out before the beginning of the treatment for both groups and at a second time after four days of therapy at full dosage, when blood was also drawn for determination of serum levels of the antipsychotic. Statistical analysis included repeated measures ANOVA, Fisher Exact Test and Indipendent T Test. Results: Mean QTc intervals significantly increased in Group 2 (24 ± 21 ms) however this was not the case in Group 1 (-1 ± 30 ms) (Repeated measures ANOVA p < 0,01). Furthermore we found a significant difference in the number of patients who exceeded the threshold of borderline QTc interval value (450 ms) between the two groups, with seven patients in Group 2 (38%) compared to one patient in Group 1 (7%) (Fisher Exact Text, p < 0,05). Conclusions: No significant prolongation of the QT interval was found following monotherapy with an antipsychotic agent, while combination of these drugs with antidepressants caused a significant QT prolongation. Careful monitoring of the QT interval is suggested in patients taking a combined treatment of antipsychotic and antidepressant agents. © 2005 Sala et al; licensee BioMed Central Ltd.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation
    Baracaldo-Santamaria, Daniela
    Llinas-Caballero, Kevin
    Miguel Corso-Ramirez, Julian
    Martin Restrepo, Carlos
    Alberto Dominguez-Dominguez, Camilo
    Janeth Fonseca-Mendoza, Dora
    Alberto Calderon-Ospina, Carlos
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (15)
  • [42] Drug-induced prolongation of the QT interval: why the regulatory concern?
    Shah, RR
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2002, 16 (02) : 119 - 124
  • [43] Drug-Induced QT Interval Prolongation in Children: Are the Kids Alright?
    Tisdale, James E.
    [J]. CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2016, 69 (03): : 183 - 184
  • [44] Drug-Induced QT-Interval Prolongation: Considerations for Clinicians
    Li, Edward C.
    Esterly, John S.
    Pohl, Shaunte
    Scott, Shane D.
    McBride, Brian F.
    [J]. PHARMACOTHERAPY, 2010, 30 (07): : 684 - 701
  • [45] QT interval prolongation and antiretroviral treatment: Another point of interest
    Chinello, Pierangelo
    Petrosillo, Nicola
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (10) : 1388 - 1389
  • [46] Perianesthesia Implications and Considerations for Drug-Induced QT Interval Prolongation
    Aroke, Edwin N.
    Nkemazeh, Rolland Z.
    [J]. JOURNAL OF PERIANESTHESIA NURSING, 2020, 35 (02) : 104 - 111
  • [47] Drug-induced QT interval prolongation: mechanisms and clinical management
    Nachimuthu, Senthil
    Assar, Manish D.
    Schussler, Jeffrey M.
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2012, 3 (05) : 241 - 253
  • [48] Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling
    Warnier, Miriam J.
    Holtkamp, Frank A.
    Rutten, Frans H.
    Hoes, Arno W.
    de Boer, Anthonius
    Mol, Peter G. M.
    De Bruin, Marie L.
    [J]. DRUG DISCOVERY TODAY, 2014, 19 (09) : 1294 - 1297
  • [49] Drug-induced prolongation of the QT interval: What's the point?
    White, PF
    Abrao, J
    [J]. ANESTHESIOLOGY, 2006, 104 (02) : 386 - 387
  • [50] Clinical Background and Evaluation of Drug-Induced Prolongation of QT Interval
    Katoh, Takao
    [J]. JOURNAL OF ARRHYTHMIA, 2009, 25 (02) : 56 - 62